^
Association details:
| Biomarker: | CXCR4 overexpression |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Regimen: | (fludarabine IV + cyclophosphamide + Rituxan (rituximab)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients
Excerpt:
Fludarabine, cyclophosphamide, and rituximab (FCR) was the standard treatment...In conclusions, expression of CXCR4 in newly diagnosed CLL is significantly high. CXCR4 increased expression is associated with poor prognosis and resistance to the therapy.so it can be used as prognostic tool.
